When does the mercaptopurine (6-MP) patent expire?
Mercaptopurine (6-mercaptopurine) is an older small-molecule oncology drug, so it does not have a single, widely cited “next” patent-expiration year in the way newer branded drugs do. The drug’s key IP would typically be driven by older primary patents and later, narrower protections (for specific formulations, processes, or brand exclusivities), which can vary by country and by product (brand vs. generic; immediate-release vs. other formulations).
How can I find the exact patent-expiration year for my country and brand?
Patent expiration is jurisdiction- and product-specific. To get the correct year, you need:
1) the exact marketed product name (brand) you mean,
2) the country/region (US, EU, UK, etc.), and
3) which patent family or formulation/process you’re tracking.
DrugPatentWatch.com is one way to look up relevant listed patents and compute/identify expiration timing for a specific drug entry (and often for specific patent families). You can start from the site here: DrugPatentWatch: mercaptopurine.
If you’re asking about exclusivity (not patents), what matters?
For older drugs, “availability dates” are often better explained by:
- generic entry history (when the first generic launched), and
- any remaining regulatory exclusivities that are separate from patents.
Those timelines can differ from patent expiry and can be especially relevant where multiple patents remain filed or where different patents cover different aspects of the product.
What I need to answer with a single year
Reply with:
- the country/region (e.g., US or EU), and
- the specific product/strength/brand name you’re referring to,
and I can narrow it down to the most relevant patent(s) and the associated expiration year.